VERTEX PHARMACEUTICALS INC (VRTX)
Sector: Health Care
Sector: Health Care
VERTEX PHARMACEUTICALS INC - Executive Compensation
EVP & Chief Operating and Financial Officer
Executive Compensation
Charles F. Wagner, Jr. serves as the Executive Vice President and Chief Financial Officer at Vertex Pharmaceuticals Incorporated, a global biotechnology company renowned for its focus on developing transformative medicines for serious diseases. Wagner joined Vertex in 2001, initially taking on the role of Vice President and Corporate Controller. Over the years, he has demonstrated exceptional leadership and financial acumen, which led to his promotion to Chief Financial Officer in 2006, and subsequently to his current position as Executive Vice President in 2009. His tenure at Vertex has been marked by significant growth and success, particularly in the company's cystic fibrosis franchise, which has revolutionized treatment options for patients worldwide. Before joining Vertex, Wagner held various financial leadership positions that honed his expertise in corporate finance and strategic planning. He began his career at Ernst & Young LLP, where he worked as an auditor, gaining deep insights into financial reporting and compliance. Following his time at Ernst & Young, he served as the Director of Finance at Genzyme Corporation, another prominent biotechnology firm, where he played a key role in financial operations and strategic initiatives. Wagner's comprehensive background in finance and his strategic vision have been instrumental in steering Vertex through its various stages of growth and innovation. In his current role at Vertex, Wagner oversees the company's global financial strategy, which includes managing financial planning and analysis, treasury, tax, and investor relations. Under his leadership, Vertex has successfully navigated complex financial landscapes, ensuring sustainable growth and profitability. Wagner's strategic foresight has been crucial in securing funding for research and development, enabling the company to advance its pipeline of novel therapies. His contributions have not only bolstered Vertex's financial health but also reinforced its position as a leader in the biotechnology industry. Wagner holds a Bachelor of Science degree in Business Administration from the University of Vermont and is a Certified Public Accountant.